BioCentury
ARTICLE | Company News

Oxford BioMedica, Microsoft join on digital tools to optimize lentiviral production

March 12, 2019 9:38 PM UTC

In the latest example of how digital computing is increasingly interfacing with biomanufacturing to optimize yields and purity, Oxford BioMedica on Tuesday entered a two-year R&D collaboration with Microsoft to identify the optimal conditions for improving the yield and quality of Oxford BioMedica's lentiviral vectors.

As part of its Station B initiative, Microsoft Corp. (NASDAQ:MSFT) will contribute its cloud computing and machine learning capabilities to develop computational models for advancing the next generation of gene therapy vectors for Oxford BioMedica plc (LSE:OXB). ...